-- Amag, Aviat, CareFusion, Netflix, Vivus: U.S. Equity Movers
-- B y   I n y o u n g   H w a n g
-- 2012-01-09T21:22:58Z
-- http://www.bloomberg.com/news/2012-01-08/ebay-inhibitex-joy-global-robert-half-u-s-equity-preview.html
Shares of the following companies had
unusual moves in U.S. market trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in  New York .  Amag Pharmaceuticals Inc. (AMAG)   retreated 10 percent,
the most since Aug. 8, to $16.65. The pharmaceutical company
said it had fourth-quarter revenue of $14.3 million to $15
million, below the average analyst estimate of $16 million.  Aviat Networks Inc. (AVNW)   rose 14 percent, the most
since Feb. 4, to $2.02. The maker of microwave radios that are
used to connect cellphone towers with the wireless network
reaffirmed its second-quarter revenue estimate of as much as
$110 million, compared with the average analyst estimate for
$106 million, data compiled by Bloomberg show.  CareFusion Corp. (CFN)   fell the most in the Standard &
Poor’s 500 Index, erasing 8.6 percent to $23.28. The maker of
products to reduce hospital infections and monitor medical
safety reduced the low end of its fiscal 2012 earnings forecast
to $1.75 a share as preliminary results for the second quarter
missed analysts’ estimates.  Con-way Inc. (CNW)   retreated 4 percent, the most since
Nov. 23, to $28.87. The U.S. trucking company was cut to
“hold” from “buy” at BB&T Capital Markets.  GameStop Corp. (GME)   dropped 3.5 percent, the most since
Nov. 16, to $23.99. The world’s largest video-game retailer cut
its fourth-quarter and year comparable sales forecast.  Inhibitex Inc. (INHX)   soared 140 percent, the biggest
gain in the Russell 2000 Index, to $23.70. Bristol-Myers Squibb
Co. (BMY US) agreed to buy the Alpharetta, Georgia-based
biopharmaceutical firm to boost its position in hepatitis C
medicines.  Other hepatitis C drug developers also rallied.  Idenix
Pharmaceuticals Inc. (IDIX)   surged 37 percent to $9.66.
 Achillion Pharmaceuticals Inc. (ACHN)   jumped 23 percent to
$9.72.  IPC The Hospitalist Co. (IPCM)   fell 33 percent, the most
since it went public in January 2008, to $30.61. The provider of
administrative services for doctors said it earned no more than
$1.74 a share last year, less than the average analysts’
estimate of $1.77 a share.  Mako Surgical Corp. (MAKO)   rose 8 percent to $31.07, the
highest price since Nov. 16. The maker of orthopedic surgery
devices said it expects to sell 56 to 62 systems this year, with
11,000 to 13,000 procedures performed. William Blair & Co. said
the forecast beat its expectation and is “a reflection of the
strong demand for robotically assisted orthopedic procedures.”  Netflix Inc. (NFLX)   added 14 percent to $98.18, for the
biggest advance in the  S&P 500 . The owner of the streaming and
DVD-by-mail service forecast it will attract millions of
subscribers within a few years to the Internet film and
television service it started in the U.K. and Ireland today,
taking on  Amazon Inc.’s (AMZN)   Lovefilm.  Questcor Pharmaceuticals Inc. (QCOR)   jumped 8.2 percent,
the most since Oct. 26, to $42.14. The  drug company  said its
paid prescription sales were “strong” in the fourth quarter of
last year and it may start a pilot selling program in
rheumatology this year.  Smith Micro Software Inc. (SMSI)   gained 9.9 percent to
$1.44, the highest price since Oct. 18. The communications-
software provider for wireless carriers and phone makers said
 Sprint Nextel Corp. (S)   selected the company’s Mobile Network
Director for traffic management between networks.  Theravance Inc. (THRX)   plunged 19 percent, the most
since October 2008, to $16.39. Relovair, an experimental
medicine that the maker of treatments for respiratory disorders
and bacterial infections shares with GlaxoSmithKline Plc (GSK
LN), failed to beat an existing drug in a study.  Vivus Inc. (VVUS)   rallied 15 percent to $11.65, the
highest price since July 2010. The maker of experimental weight-
loss pill Qnexa said U.S. regulators ordered changes to a
proposed warning label for the treatment.  To contact the reporter on this story:
Inyoung Hwang in New York at 
 ihwang7@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at 
 nbaker7@bloomberg.net  